+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP

Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP

Journal of Clinical Lipidology 12(3): 784-800.E4

Statins impact the metabolism, concentrations, composition, and function of circulating lipoproteins. We evaluated time course relationships between statin-mediated reduction in atherogenic apolipoprotein B (ApoB)-containing particles and dynamic intravascular remodeling of ApoAI-containing lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome. Insulin-resistant, hypertriglyceridemic, hypercholesterolemic, obese males (n = 12) were treated with pitavastatin (4 mg/d) and response evaluated at 6, 42, and 180 days. Reduction in low-density lipoprotein (LDL) cholesterol, ApoB, and triglycerides (TGs) was essentially complete at 42 days (-38%, -32%, and -35%, respectively); rapid reduction equally occurred in remnant cholesterol, ApoCII, CIII, and E levels (day 6; -35%, -50%, -23%, and -26%, respectively). Small dense LDLs (LDL4 and LDL5 subpopulations) predominated at baseline and were markedly reduced on treatment (-29% vs total LDL mass). Cholesteryl ester (CE) transfer protein activity and mass decreased progressively (-18% and -16%, respectively); concomitantly, TG depletion (up to -49%) and CE enrichment occurred in all high-density lipoprotein (HDL) particle subpopulations with normalization of CE/TG mass ratio at 180 days. ApoAI was redistributed from LpAI to LpAI:AII particles in HDL2a and HDL3a subpopulations; ApoCIII was preferentially depleted from LpAI:AII-rich particles on treatment. Overall, statin action exhibits duality in mixed dyslipidemia, as CE transfer protein-mediated normalization of the HDL CE/TG core lags markedly behind subacute reduction in elevated levels of atherogenic ApoB-containing lipoproteins. Normalization of the HDL neutral lipid core is consistent with enhanced atheroprotective function. The HDL CE/TG ratio constitutes a metabolomic marker of perturbed HDL metabolism in insulin-resistant states, equally allowing monitoring of statin impact on HDL metabolism, structure, and function.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 058989130

Download citation: RISBibTeXText

PMID: 29574070

DOI: 10.1016/j.jacl.2018.02.001

Related references

Efficacy of statin monotherapy or in combination with coenzyme a capsule in patients with metabolic syndrome and mixed dyslipidemia. Journal of Clinical Medicine Research 7(6): 446-452, 2015

Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia. Journal of Lipid Research 56(12): 2381-2392, 2015

Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis. Journal of Clinical Lipidology 12(3): 810-821.E1, 2018

CETP TaqIB polymorphism in Turkish adults: association with dyslipidemia and metabolic syndrome. Anadolu Kardiyoloji Dergisi 8(5): 324-330, 2008

P296 Effects Of Fenofibric Acid In Combination With Statin Therapy On Low-Density Lipoprotein Particle Size In Patients With Mixed Dyslipidemia. Atherosclerosis Suppl.s 11(2): 79-80, 2010

Managing the dyslipidemia of metabolic syndrome: beyond statin therapy. Metabolic Syndrome and Related Disorders 10(3): 159-160, 2012

Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?. International Journal of Cardiology 110(2): 276-277, 2006

Implication of the new low-density lipoprotein goals in dyslipidemia management of patients with acute coronary syndrome. Mayo Clinic Proceedings 82(5): 551-555, 2007

Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia. Journal of Lipid Research 57(11): 2073-2087, 2016

Common CETP polymorphisms modify the efficacy of statin therapy in diabetes mellitus type 2 patients with diabetic dyslipidemia. Circulation 104(17 Suppl.): II 177, 2001

Management of dyslipidemia USING temporal flavocitrin inclusion in course of long-term statin therapy of patients with chd and metabolic syndrome. Atherosclerosis 235(2): E257-E258, 2014

Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model. Angiology 62(2): 144-154, 2011

Metabolic Syndrome, Dyslipidemia and Regulation of Lipoprotein Metabolism. Current Diabetes Reviews 14(5): 427-433, 2018

Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opinion on PharmacoTherapy 12(9): 1429-1438, 2011

Pharmacotherapy of Mixed Dyslipidemia in the Metabolic Syndrome. Current Clinical Pharmacology 5(2): 133-139, 2010